CBPO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CBPO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
China Biologic Products Holdings has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for China Biologic Products Holdings's Piotroski F-Score or its related term are showing as below:
During the past 13 years, the highest Piotroski F-Score of China Biologic Products Holdings was 8. The lowest was 4. And the median was 6.
The historical data trend for China Biologic Products Holdings's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biologic Products Holdings Annual Data | |||||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||||
Piotroski F-Score | Get a 7-Day Free Trial | 7.00 | 5.00 | 6.00 | 6.00 | 5.00 |
China Biologic Products Holdings Quarterly Data | ||||||||||||||||||||
Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | |
Piotroski F-Score | Get a 7-Day Free Trial | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 |
For the Biotechnology subindustry, China Biologic Products Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, China Biologic Products Holdings's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where China Biologic Products Holdings's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Sep20) TTM: | Last Year (Sep19) TTM: |
Net Income was 12.452 + 53.384 + 35.682 + 39.545 = $141.1 Mil. Cash Flow from Operations was 72.915 + 75.744 + 59.726 + 53.023 = $261.4 Mil. Revenue was 102.158 + 162.591 + 111.112 + 138.536 = $514.4 Mil. Gross Profit was 63.991 + 100.989 + 76.374 + 92.466 = $333.8 Mil. Average Total Assets from the begining of this year (Sep19) to the end of this year (Sep20) was (1892.808 + 1937.858 + 1984.726 + 2024.424 + 2139.513) / 5 = $1995.8658 Mil. Total Assets at the begining of this year (Sep19) was $1,892.8 Mil. Long-Term Debt & Capital Lease Obligation was $0.0 Mil. Total Current Assets was $1,495.0 Mil. Total Current Liabilities was $124.4 Mil. |
Net Income was 34.907 + 37.692 + 41.647 + 47.017 = $161.3 Mil. Revenue was 114.929 + 129.784 + 135.696 + 136.107 = $516.5 Mil. Gross Profit was 77.347 + 85.544 + 90.903 + 88.641 = $342.4 Mil. Average Total Assets from the begining of last year (Sep18) to the end of last year (Sep19) was (1974.368 + 2009.979 + 2036.259 + 1994.336 + 1892.808) / 5 = $1981.55 Mil. Total Assets at the begining of last year (Sep18) was $1,974.4 Mil. Long-Term Debt & Capital Lease Obligation was $0.0 Mil. Total Current Assets was $1,259.0 Mil. Total Current Liabilities was $120.2 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
China Biologic Products Holdings's current Net Income (TTM) was 141.1.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
China Biologic Products Holdings's current Cash Flow from Operations (TTM) was 261.4.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Sep19) |
= | 141.063 | / | 1892.808 | |
= | 0.07452578 |
ROA (Last Year) | = | Net Income | / | Total Assets (Sep18) |
= | 161.263 | / | 1974.368 | |
= | 0.08167829 |
China Biologic Products Holdings's return on assets of this year was 0.07452578. China Biologic Products Holdings's return on assets of last year was 0.08167829.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
China Biologic Products Holdings's current Net Income (TTM) was 141.1. China Biologic Products Holdings's current Cash Flow from Operations (TTM) was 261.4.
==> 261.4 > 141.1 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Sep20) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Sep19 to Sep20 |
= | 0 | / | 1995.8658 | |
= | 0 |
Gearing (Last Year: Sep19) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Sep18 to Sep19 |
= | 0 | / | 1981.55 | |
= | 0 |
China Biologic Products Holdings's gearing of this year was 0. China Biologic Products Holdings's gearing of last year was 0.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Sep20) | = | Total Current Assets | / | Total Current Liabilities |
= | 1494.958 | / | 124.449 | |
= | 12.01261561 |
Current Ratio (Last Year: Sep19) | = | Total Current Assets | / | Total Current Liabilities |
= | 1258.987 | / | 120.234 | |
= | 10.47113961 |
China Biologic Products Holdings's current ratio of this year was 12.01261561. China Biologic Products Holdings's current ratio of last year was 10.47113961.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
China Biologic Products Holdings's number of shares in issue this year was 39.536. China Biologic Products Holdings's number of shares in issue last year was 38.436.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 333.82 | / | 514.397 | |
= | 0.64895402 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 342.435 | / | 516.516 | |
= | 0.66297075 |
China Biologic Products Holdings's gross margin of this year was 0.64895402. China Biologic Products Holdings's gross margin of last year was 0.66297075.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Sep19) |
= | 514.397 | / | 1892.808 | |
= | 0.27176396 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Sep18) |
= | 516.516 | / | 1974.368 | |
= | 0.2616108 |
China Biologic Products Holdings's asset turnover of this year was 0.27176396. China Biologic Products Holdings's asset turnover of last year was 0.2616108.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 1 | + | 1 | + | 0 | + | 1 | + | 1 | + | 1 | + | 0 | + | 0 | + | 1 | |
= | 6 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
China Biologic Products Holdings has an F-score of 6 indicating the company's financial situation is typical for a stable company.
China Biologic Products Holdings (NAS:CBPO) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of China Biologic Products Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhijing Cbpo Liu | officer: Corporate Vice President | 19 CHAOYANG PARK ROAD 18/F, JIALONG INTERNATIONAL BUILDING BEIJING F4 100125 |
Sean Shao | director | 21ST FLOOR, EVERBRIGHT BANK BUILDING, ZHUZILIN, FUTIAN DISTRICT, SHENZHEN, GUANGDONG F4 518040 |
David Gao | director, officer: Chief Executive Officer | C/ BEIJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
Albert Yeung | director | C/O BEIJING MED-PHARM CORPORATION 600 WEST GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
David Hui Li | director | C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 |
Min Fang | director | UNIT 2206, BUND CENTER OFFICE TOWER NO. 222 YANAN ROAD (EAST) SHANGHAI F4 200002 |
Zhijun Tong | director | C/O BMP SUNSTONE CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
Joseph Chow | director | 10110 SORRENTO VALLEY ROAD SUITE C SAN DIEGO CA 92121 |
Yungang Lu | director | 4TH FLOOR, ZHONGDIAN INFORMATION TOWER 6 ZHONGGUANCUN S. ST., HAIDIAN DIST. BEIJING F4 100086 |
Warburg Pincus Llc | 10 percent owner | 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
Wp X Biologics Llc | director, 10 percent owner | C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK X1 10017 |
Warburg Pincus X Partners, L.p. | director, 10 percent owner | C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
Warburg Pincus Private Equity X, L.p. | director, 10 percent owner | C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
Warburg Pincus X Gp L.p. | director, 10 percent owner | C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
Warburg Pincus X, L.p. | director, 10 percent owner | C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
From GuruFocus
By PRNewswire PRNewswire • 04-20-2021
By PRNewswire PRNewswire • 07-27-2019
By [email protected] insider • 06-05-2020
By PRNewswire PRNewswire • 04-30-2019
By PRNewswire PRNewswire • 05-21-2020
By PRNewswire PRNewswire • 11-19-2020
By PRNewswire PRNewswire • 09-19-2019
By PRNewswire PRNewswire • 03-01-2021
By PRNewswire PRNewswire • 05-12-2020
By PRNewswire PRNewswire • 09-24-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.